Dec 17,2018

Pear Therapeutics Announces Initiation of Proof of Concept Study for Prescription Digital Therapeutic in Development for the Treatment of Schizophrenia

Pear Therapeutics, Inc. today announced the initiation of a Phase 2, proof of concept study for its prescription digital therapeutic in development for schizophrenia. The treatment, known as Pear-004, is designed to deliver multimodal neurobehavioral interventions to improve symptoms and functioning of people with schizophrenia.

PRODUCT

#mobile app

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Dec 13,2017

AmalgamRX to launch stress reduction app for patients with psoriasis, psoriatic arthritis

Digital therapy platform AmalgamRX has just announced the upcoming launch of its new app, Beyond, which aims to help patients living with psoriasis and psoriatic arthritis providing them resources to manage stress. Based on cognitive behavioral strategies, the app is specifically designed to help patients with the stress that can cause flare-ups. Through activities and resources, it gives user techniques for reducing their stress and increasing their optimism level.

PRODUCT

#mobile app

#coaching

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 25,2017

Click Therapeutics Announces Multiple Publications of Clinical Data Supporting Digital Therapeutics™ Programs for Smoking Cessation and Major Depressive Disorder

Click Therapeutics announces today multiple publications of research data supporting its digital therapeutics for smoking cessation and major depressive disorder. The results of a 416-person clinical trial of Clickotine, a digital therapeutic for smoking cessation, have been published in JMIR mHealth and uHealth. This trial found Clickotine to be engaging for users (100.6 app opens on average), as well as efficacious. Interim efficacy results of Click’s novel cognitive-emotional digital therapeutic for major depressive disorder show that compared to an active control group, Click’s intervention resulted in significantly greater MDD symptom reduction after the 6-week regimen (42.9% compared to 15.7% in the control group).

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Jun 08,2017

This adorable chatbot wants to talk about your mental health

Woebot, one of the first chatbots of its kind, is powered by artificial intelligence not to tackle your deepest problems, but to improve your mood, and even alleviate symptoms of depression. The chatbot also represents the risky yet essential innovation happening at the intersection of mental health care and technology.

PRODUCT

#chatbot

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 13,2015

Study Shows Omada Health’s Online DPP Participants Maintained Reductions in Weight and Average Blood Sugar Levels

According to a study published Friday in the peer-reviewed Journal of Medical Internet Research (JMIR), participants in Omada Health’s online diabetes prevention program Prevent maintained reductions in body weight and average blood sugar levels across a two-year horizon. Becoming the first digital health company to publish two-year, peer-reviewed outcomes, Omada Health programs continue to demonstrate best-in-class clinical results for using intensive behavioral counseling to spur and maintain lifestyle changes. Prevent participants also demonstrated higher rates of program completion, and continued to engage with Prevent after the 12-month curriculum concluded.

CLINICAL STUDY

#coaching

#cbt

View Analyst & Ambassador Comments
Go to original news
Nov 03,2015

ShapeUp Select™ Unites Best-In-Class Wellness Vendors in Employee Wellbeing Platform

ShapeUp, the leading provider of global wellbeing solutions, has expanded its holistic offering to include products and programs from innovative, specialized partners that are fully integrated into its wellbeing platform. The partners include Claritas Mindsciences who offer evidence-based digital programs for smoking cessation (Craving to Quit) and healthy eating (Eat Right: NOW!). ShapeUp Select allows benefits administrators to easily add a variety of new and innovative wellbeing programs to their employee offering.

PRODUCT

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 05,2014

PARTNERSHIP WITH ANYCARE GMBH | SILVERCLOUD HEALTH

SilverCloud Health, a global provider of behavioural and mental wellness online solutions, announced further expansion into the European healthcare market through a strategic partnership with German healthcare provider AnyCare GmbH. SilverCloud Health will work with AnyCare to translate its online platform and therapeutic programmes for stress, anxiety, and depression into German.

COLLABORATION PARTNERSHIP

#product & service

#cbt

View Analyst & Ambassador Comments
Go to original news
Jan 17,2022

5 Takeaways: The Rise Of Digital Therapeutics (DTx) In 2022

At the BIOMEDevice Conference last month, Scott Thielman moderated a panel titled Is There an App for That? The Rise of Prescription Digital Therapeutics. In the article, there are five takeaways from the experts’ discussion.

#cbt

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Jan 18,2022

Mahana Therapeutics Selected for Prestigious Digitalhealth.London Accelerator Program

Mahana Therapeutics, a leading developer of prescription digital therapeutics designed to empower people living with chronic health conditions, announced that Mahana has been selected for the DigitalHealth.London’s Accelerator programme.The program will help Mahana Therapeutics better engage with the NHS to accelerate adoption of Mahana IBS in clinical practice. Mahana IBS has the potential to deliver significant cost savings for the NHS and provide a new way of treating IBS for millions of people affected. Mahana IBS delivers cognitive behavioral therapy (CBT) to empower adults with irritable bowel syndrome (IBS) to lessen the severity of symptoms.

PRODUCT

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Jan 20,2022

Digital Health company HelloBetter strikes partnership with Teva Pharmaceuticals in Germany

HelloBetter, a Berlin-based digital health company, and ratiopharm, a subsidiary of Teva Pharmaceuticals, announced a partnership to market a digital therapeutic for patients suffering from chronic pain, labelled HelloBetter ratiopharm Chronic Pain. Having received regulatory approval by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), the German equivalent of the FDA, their product will now be available free of charge on prescription to all adults in Germany.

COLLABORATION PARTNERSHIP

#product & service

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Subscribe to CBT